It's all by design
It's all by design
It's all by design
 
SCILEX is more than just a pharmaceutical company. It’s a team of passionate and dedicated people who have faith in forward-thinking technologies and who believe that helping patients better manage their pain can lead toward a better quality of life. Learn more about the people who make up what we think is a pretty amazing place.
 

Principled by design

We are committed to following these tenets of good business that have
helped shape the Mission, Vision, and Values by which we run SCILEX.

MISSION

SCILEX Pharmaceuticals responsibly develops and brings branded pharmaceutical products to market using groundbreaking technologies that maximize the quality of life for all.

VISION

We are uncompromising in our focus to become the global pharmaceutical leader in pain management. We are committed to social, environmental, economic, and ethical responsibility. Dedicated to using international partnerships, we strive to deliver the next generation of trailblazing products that are responsible by design.

VALUES

Responsibility: We are determined to relieve pain for all of our stakeholders.

Diversity: We are strengthened by the multiplicity of our experiences, backgrounds, outlooks, and partnerships.

Excellence: We are committed to being part of the solution the right way.

Integrity: When it comes to doing the right thing, we do not compromise.

Quality: Our products are built on a foundation of proven trust.

Accountability: Our outlook is socially, environmentally, economically, and ethically focused.

It's all by design
It's all by design
It's all by design

Experienced by design

Comprising industry veterans and visionary thinkers, the SCILEX Board of Directors is a management team that has decades of pharmaceutical experience with a strong track record of success. The members offer a collective knowledge of drug development, finance, accounting, regulatory, legal, sales, and marketing to help advise and counsel the day-to-day Executive Team.

 

Henry Ji, Ph.D

Henry Ji, Ph.D., co-founded and has served as a director of Sorrento since January 2006, and as its Chief Executive Officer and President since September 2012. Dr. Ji served as Sorrento’s Chief Scientific Officer from November 2008 to September 2012 and as its Interim Chief Executive Officer from April 2011 to September 2012.

Dr. Ji served as VP of Sales and Business Development at CombiMatrix, and was responsible for strategic technology alliances. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as VP of Business Development at Stratagene (later acquired by Agilent Technologies), a biotechnology company. In 1997, Dr. Ji co-founded Stratagene Genomics, a wholly-owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer and Director from its founding until 1999.

Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. He held many executive positions in biotechnology and life sciences companies during his career.

Kenji Hakoda

Kenji Hakoda has more than twenty years of management experience in the global chemical trading industry, including 11 years in Korea and Taiwan with a focus on seeking new business development. Mr. Hakoda currently serves as the Pharmaceutical Division Director and Chief Operating Officer for Itochu Chemical Frontier Corporation (“ICF”) in Japan, a member of ITOCHU Corporation, a Fortune Global 500 Company and one of the three leading Sogo Shosha (general trading companies) in Japan. In 1983 Mr. Hakoda entered ITOCHU Corporation as an expert in chemical trading. In the past five years he has served the pharmaceutical industry, by utilizing a global network to procure API(Active Pharmaceutical Ingredient) and FDF(Finished Dosage Form), and also contributing to the development of biosimilars.  Mr. Hakoda holds a B.S. in Applied Chemistry from the Engineering Department at Yokohama National University in Japan.  
 

Jaisim Shah

Mr. Shah currently serves as the Chief Executive Officer and board member at Semnur Pharmaceuticals. Prior to Semnur, Mr. Shah was a consultant to several businesses, including Sorrento Therapeutics. From 2011 through 2012, Mr. Shah was the Chief Business Officer of Elevation Pharmaceuticals. Prior to Elevation, Mr. Shah was President of Zelos Therapeutics, where Mr. Shah focused on financing and business development. Prior to Zelos, Mr. Shah was the SVP and Chief Business Officer at CytRx. Previously, Mr. Shah was Chief Business Officer at Facet Biotech and PDL BioPharma where he completed numerous licensing/ partnering and strategic transactions. Prior to PDL, Mr. Shah was at Bristol-Myers Squibb, most recently as Vice President of Global Marketing where he received the “Presidents Award” for completing one of the most significant collaborations in the company’s history. Previously, Mr. Shah was at F. Hoffmann-La Roche in international marketing and was global business leader for corporate alliances with Genentech and Idec. Mr. Shah holds an MA in Economics from the University of Akron and an MBA from University of Oklahoma.
 

Alexander Wu

Yue Alexander Wu, Ph.D.

Dr. Wu is co-founder, President, Chief Executive Officer and Chief Scientific Officer of Crown Bioscience International, a leading global drug discovery and development solutions company, which he co-founded in 2006. From 2004 to 2006, Dr. Wu was Chief Business Officer of Starvax International Inc. in Beijing, China, a biotechnology company focusing on oncology and infectious diseases. From 2001 to 2004, Dr. Wu was a banker with Burrill & Company where he was head of Asian Activities. Dr. Wu received his Ph.D. in Molecular Cell Biology and his MBA from University of California at Berkeley. He earned an M.S. in Biochemistry from University of Illinois, Urbana-Champaign and his B.S. in Biochemistry from Fudan University in Shanghai, China.

Leadership by design

Legal, Finance, Clinical, Regulatory, and Product Commercialization

The mission of the Executive Team is to bolster our proprietary pain management technology by employing years of expertise that comes with overseeing market access, commercialization, advocacy, and government affairs programs. These seasoned professionals bring SCILEX a type of leadership that is unmatched in the pharmaceutical industry.

 

Henry Ji, Ph.D

Henry Ji, Ph.D., co-founded and has served as a director of Sorrento since January 2006, and as its Chief Executive Officer and President since September 2012. Dr. Ji served as Sorrento’s Chief Scientific Officer from November 2008 to September 2012 and as its Interim Chief Executive Officer from April 2011 to September 2012.

Dr. Ji served as VP of Sales and Business Development at CombiMatrix, and was responsible for strategic technology alliances. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as VP of Business Development at Stratagene (later acquired by Agilent Technologies), a biotechnology company. In 1997, Dr. Ji co-founded Stratagene Genomics, a wholly-owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer and Director from its founding until 1999.

Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. He held many executive positions in biotechnology and life sciences companies during his career.

William-Pedranti

William Pedranti, JD

William Pedranti has more than 15 years of experience serving as senior counsel and as a senior executive at leading biotech and pharmaceutical companies, including the past six years at Scilex, which he co-founded. Previously, Mr. Pedranti was Vice President and General Counsel for Spectrum Pharmaceuticals and helped oversee its transformation from a clinical stage company to a commercial company. During Mr. Pedranti’s career, he has facilitated equity financing transactions that have raised more than $220 million and participated in the acquisition of over a dozen products. Additionally, Mr. Pedranti has been responsible for out-licensing transactions that generated more than $65 million in upfront fees. He has also supported the commercial launch of multiple drug products. Prior to Spectrum Pharmaceuticals, Mr. Pedranti provided corporate, transactional, regulatory, and M&A advice to small and large companies in various industries, including life sciences at the international law firm Latham & Watkins LLP. Mr. Pedranti received his BS in Business from the University of Southern California and his JD from Georgetown University Law Center.
 

George Ng, JD

As President of all business matters, George K. Ng oversees all company business operations, including the administrative, business development, finance, human resources, marketing, sales and commercial operations departments. Mr. Ng is responsible for developing, implementing and leading the company’s strategy and efforts for commercialization. Prior to joining Sorrento Therapeutics, Mr. Ng held various senior management positions, including General Counsel, Chief Compliance Officer and Chief Intellectual Property Counsel, with publicly-traded, global biotechnology and pharmaceutical companies, including BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and Alpharma, Inc. (now, a part of Pfizer Inc.). Previously, in private practice, Mr. Ng was a partner in two AMLAW 200 law firms where he had leadership roles, including establishing the life sciences practice group and heading it as the national co-chair. Mr. Ng is also a past President-Elect of the Pan Asian Lawyers of San Diego (PALSD) and was recently appointed to the Leadership Development Committee of the Wake County Bar Association in North Carolina. He is a frequent speaker and noted authority on legal, compliance and business issues in the life sciences, with past speaking engagements at the 2011 BIO International Convention and various pharmaceutical congresses and conferences. Among his multiple awards and commendations, Mr. Ng is a recipient of the 2015 Outstanding 50 Asian Americans in Business Award and past recipient of M&A Advisor’s Top 40 Under 40 Award (in 2012), and, in 2010, MDB Capital recognized Mr. Ng (and the company where he led the intellectual property efforts) for its Best and Brightest Award and as an Astrum Award nominee for a pharmaceutical patent portfolio that he managed and developed. Mr. Ng obtained his J.D. from the University of Notre Dame and a B.A.S. (dual degree) in Biochemistry and Economics from the University of California, Davis.
Chris Duncan

Chris Duncan

Chris Duncan has over 25 years of healthcare experience in sales, marketing, business and commercial development. Prior to Scilex, he provided consulting services for companies in biotech, pharmaceuticals, specialty pharmacy, pharmacogenetics, toxicology and data analytics. Mr. Duncan has held various Marketing roles in the pharmaceutical and biotech industries in multiple therapeutic areas including pain management, diabetes, oncology, hepatology, dermatology, allergy and respiratory. Most recently he was Executive Director, Marketing and Product Strategy at Nektar Therapeutics. Prior to Nektar, Mr. Duncan was at Zogenix, Amylin Pharmaceuticals, Ligand Pharmaceuticals, Vical and Schering Plough where he consistently created value and worked to bring products and services to clinicians and patients.

Chris has also served on the Board of Directors for the American Chronic Pain Association. Mr. Duncan holds a B.A. in Business from the University of Arizona and a M.B.A. from the University of Redlands.
Mike Sweeting

Mike Sweeting

Mike Sweeting has over 27 years of pharmaceutical experience serving in a variety of senior leadership roles in Market Access and Commercial Sales with the depth of his experience residing in the Market Access arena where he enjoys extensive and deep-rooted relationships. Most recently Mr. Sweeting was responsible for building the Market Access team for Questcor Pharmaceuticals and initiated all payer facing value proposition and contracting strategies before the organization merged with Mallinckrodt Pharmaceuticals. Mr. Sweeting has a deep understanding of Market Access and Reimbursement complexities with expertise in buy & bill, specialty pharmacy and traditional retail distribution models, medical policy, pricing and contracting, strategic planning and pull-through strategies. Previously, Mr. Sweeting enjoyed a 23-year career at Sanofi-Aventis where he demonstrated a track record of success using strong leadership skills to manage teams of up to 250 employees, including Regional Directors, District Sales Managers, Managed Care Account Executives, Access & Reimbursement Managers and Sales Representatives, while guiding a 5M sales effort across metabolism, cardiovascular and internal medicine business units. Mr. Sweeting received his Bachelor of Science in Business from the University of Arizona.
Kalpana Patel

Kalpana Patel

Kalpana Patel, Pharm.D, Senior Director of Medical Affairs at Scilex Pharmaceuticals Inc., has 20+ years of Medical Affairs leadership and 15+ years of people management experience. At Scilex, Kalpana is responsible for leadership and strategy for the Medical Affairs group, including leading field based MSL team, medical education, grants, investigator sponsored trials, pharmacovigilance, and providing medical support for sales, marketing and managed markets team. Prior to joining Scilex, Kalpana was Senior Director and National Team Leader, Medical affairs, at Depomed Inc., where she led the successful launch of GRALISE®, a 505(b)(2) of gabapentin, for the treatment of PHN pain. Kalpana also oversaw successful integration of three additional product acquisition in the pain space (Cambia, Lazanda and Zipsor), in the management of acute and chronic pain. Prior to Depomed Inc., Kalpana has been in leadership and management roles in medical affairs at Pfizer Inc, and Johnson & Johnson, Ortho Biotech Products LP, with Clinical and Research experience in Oncology, HIV/ID, Nephrology, Critical Care and Surgery. Kalpana received her Doctor of Pharmacy from Rutgers College of Pharmacy and a Research Fellowship in Infectious Diseases at Hartford Hospital.
Kip Vought

Kip Vought

Prior to joining Scilex in November 2015, Kip Vought was a founder and VP of Regulatory and Strategic Development (RSD) of Regulus Pharmaceutical Consulting, Inc., which was acquired by Clinipace Worldwide in 2011. At Regulus/Clinipace, Kip’s Team provided strategic development pathways for client pharmaceutical products in global markets, and lead agency meetings to obtain agreement on data requirements for reginal clinical trial application and market applications. Kip’s Team also provided management of the development program in addition to preparation of clinical trial applications (eg, INDs) and market applications (eg, NDAs). Client companies included small start up to medium size pharma. The product types included NCEs, 505(b)(2)/hybrids, generics, siRNAs, and monoclonal antibodies for the treatment of various indications including analgesic, oncology, gastrointestinal, cardiovascular, and pulmonary. Kip also lead R&D/regulatory/QA acquisition and in-licensing due diligence on the behalf of financial institutions (ie, private equity, venture capital, and investment banks) and pharma companies. Prior to Regulus/Clinipace, Kip was at NaPro BioTherapeutics, Inc. that was focused on the development of oncology drug products derived from botanical products (extraction or semisynthetic). Kip started his career at Ivax Pharmaceuticals, Inc. in analytical research leading to project management in pharmaceutical development.
Matt Hoenecke

Matt Hoenecke

Matt Hoenecke has over 29 years of successful pharmaceutical and medical device experience serving in a variety of leadership roles in Commercial Sales, Key Accounts and Market Access with the depth of his experience residing in Sales Leadership. Mr. Hoenecke has held Sales Leadership roles of progressive responsibility in multiple therapeutic areas including pain management, gastroenterology, CNS, diabetes, allergy and asthma. Most recently Mr. Hoenecke served as Sr. Area Director for Synergy Pharmaceuticals and was an integral part of the successful launch of a novel agent in the GI space. Previously, Mr. Hoenecke had an 11-year career at Sanofi-Aventis where he built multiple sales teams and had a productive tenure in Market Access. Mr. Hoenecke went on to build high performing sales teams at Shire Pharmaceuticals, Aerocrine and Synergy Pharmaceuticals prior to coming to Scilex. Mr. Hoenecke received his Bachelor of Arts in General Studies from the University of Arizona.

Not your typical pharma

We’re not just your average pharmaceutical company. We’re a different breed altogether. Ours is a passionate team of talented people working together to make a difference in the world of pain management. Our team-spirited approach ensures a collaborative, engaged, and focused atmosphere where we push thinking further, fostering innovation and fervently pursuing viable solutions for patients and providers through groundbreaking technologies. We believe in the “law of science” and that we’re all entitled to live healthy and pain-free lives—because we’re patients, too. We don’t just seek answers. We seek THE answer. That’s how our team embodies being “Responsible by design.”

X

Share This Page

XS SM MD LG XL